Literature DB >> 22044440

Disseminated fusariosis and endogenous fungal endophthalmitis in acute lymphoblastic leukemia following platelet transfusion possibly due to transfusion-related immunomodulation.

Tan Aik Kah1, Ku Chui Yong, Ropilah Abdul Rahman.   

Abstract

BACKGROUND: To report a case of disseminated fusariosis with endogenous endophthalmitis in a patient with acute lymphoblastic leukemia. Transfusion-associated immune modulation secondary to platelet transfusion could play an important role in the pathophysiology of this case. CASE
PRESENTATION: A 9 year-old male with acute lymphoblastic leukemia complicated by pancytopenia and disseminated Intravascular coagulation was given platelet transfusion. He developed disseminated fusariosis and was referred to the ophthalmology team for right endogenous endophthalmitis. The infection was controlled with aggressive systemic and intravitreal antifungals.
CONCLUSION: Patients with acute lymphoblastic leukemia are predisposed to endogenous fungal endophthalmitis. Transfusion-associated immune modulation may further increase host susceptibility to such opportunistic infections.

Entities:  

Mesh:

Year:  2011        PMID: 22044440      PMCID: PMC3220630          DOI: 10.1186/1471-2415-11-30

Source DB:  PubMed          Journal:  BMC Ophthalmol        ISSN: 1471-2415            Impact factor:   2.209


  9 in total

Review 1.  Platelet transfusion therapy.

Authors:  Sherrill J Slichter
Journal:  Hematol Oncol Clin North Am       Date:  2007-08       Impact factor: 3.722

Review 2.  Transfusion-related immunomodulation (TRIM): an update.

Authors:  Eleftherios C Vamvakas; Morris A Blajchman
Journal:  Blood Rev       Date:  2007-09-04       Impact factor: 8.250

3.  ALL R-87 protocol in the treatment of children with acute lymphoblastic leukaemia in early bone marrow relapse.

Authors:  F Giona; A M Testi; R Rondelli; S Amadori; W Arcese; G Meloni; M L Moleti; A Ceci; M Pillon; E Madon; M Comis; A Pession; F Mandelli
Journal:  Br J Haematol       Date:  1997-12       Impact factor: 6.998

4.  The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: a report on the medical research council UKALLR1 study.

Authors:  S E Lawson; G Harrison; S Richards; A Oakhill; R Stevens; O B Eden; P J Darbyshire
Journal:  Br J Haematol       Date:  2000-03       Impact factor: 6.998

5.  Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients.

Authors:  U Dührsen; J L Villeval; J Boyd; G Kannourakis; G Morstyn; D Metcalf
Journal:  Blood       Date:  1988-12       Impact factor: 22.113

6.  Endogenous endophthalmitis: an 18-year review of culture-positive cases at a tertiary care center.

Authors:  Monica I Binder; Jimmy Chua; Peter K Kaiser; Gary W Procop; Carlos M Isada
Journal:  Medicine (Baltimore)       Date:  2003-03       Impact factor: 1.889

7.  Treatment of occult or late overt testicular relapse in children with acute lymphoblastic leukemia: a Pediatric Oncology Group study.

Authors:  M M Wofford; S D Smith; J J Shuster; W Johnson; G R Buchanan; M D Wharam; A K Ritchey; D Rosen; M E Haggard; B L Golembe
Journal:  J Clin Oncol       Date:  1992-04       Impact factor: 44.544

Review 8.  The platelet as an immune cell-CD40 ligand and transfusion immunomodulation.

Authors:  Neil Blumberg; Sherry L Spinelli; Charles W Francis; Mark B Taubman; Richard P Phipps
Journal:  Immunol Res       Date:  2009-01-29       Impact factor: 2.829

9.  Successful treatment of disseminated Fusarium infection after autologous bone marrow transplantation for acute myeloid leukemia.

Authors:  M J Robertson; M A Socinski; R J Soiffer; R W Finberg; C Wilson; K C Anderson; L Bosserman; D N Sang; I F Salkin; J Ritz
Journal:  Bone Marrow Transplant       Date:  1991-08       Impact factor: 5.483

  9 in total
  1 in total

1.  Identification of Fusarium from a patient with fungemia after multiple organ injury.

Authors:  Yuli Kang; Li Li; Junhao Zhu; Ying Zhao; Qiangqiang Zhang
Journal:  Mycopathologia       Date:  2013-05-24       Impact factor: 2.574

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.